Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...

Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.

Nvidia sold its entire 7.71M share stake as ARK Invest bought 1.25M shares; RXRX swung 14% before closing 2% higher Wednesday.

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other firms that ...

The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 16.03 / share. This is an increase of 8.91% from the prior estimate of 14.72 dated July 5, 2023.

Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...

Recursion Pharmaceuticals' stock experienced a 10.06% surge on Monday, indicating strong investor confidence in the company's innovations. The completion of BioHive-2 marks a pivotal moment for ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands ...

Fintel reports that on May 9, 2023, Keybanc maintained coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Overweight recommendation. As of April 24, 2023, the average one-year price ...

Based on the one-year price targets offered by 7 analysts, the average target price for Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is $10.14, with a high estimate of $14 and a low estimate of $6. The ...

We recently compiled a list of the Last Week's Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a ...